10-Q: InnovAge Reports Strong Q2 Earnings Amidst Regulatory Hurdles

InnovAge Holding Corp. posted a significant financial turnaround in its second fiscal quarter, driven by increased capitation revenue and member growth, despite facing ongoing regulatory challenges and rising operational costs.

Summary

• InnovAge Holding Corp. reported total revenues of $475.8 million for the six months ended December 31, 2025, a 14.9% increase from $414.1 million in the prior year period.
• Capitation revenue grew by 15.0% to $475.4 million, primarily due to a 5.6% increase in capitation rates and an 8.9% increase in member months.
• Net income attributable to InnovAge Holding Corp. was $18.6 million, a substantial improvement from a net loss of $18.2 million in the same period last year.
• Diluted earnings per share (EPS) improved to $0.14 from a loss of $0.13 per share year-over-year.
• Adjusted EBITDA surged by 222.3% to $39.8 million, with an Adjusted EBITDA margin of 8.4%, up from 3.0% in the prior year.
• The company served approximately 8,010 PACE participants as of December 31, 2025, operating 20 centers across six states.
• InnovAge completed the acquisition of certain pharmacy assets from Tabula Rasa HealthCare Group, Inc. (TRHC) for $4.8 million on January 2, 2025, aiming to support growth and improve pharmacy cost-management.
• A joint venture agreement was entered into with Tampa General Hospital on August 15, 2025, to develop a PACE center in Tampa, Florida, with InnovAge contributing $28.8 million for a 90% controlling interest.
• The company successfully settled a stockholder class action lawsuit for $27.0 million, with $10.1 million paid by InnovAge after insurer adjustments, and the case is now closed.
• A settlement in principle has been reached for a derivative lawsuit, expected to be fully funded by insurance proceeds, with no material loss anticipated for the company.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report given the significant financial turnaround and strong revenue growth. However, ongoing regulatory scrutiny, the California moratorium, and unresolved legal proceedings introduce notable uncertainties and temper a higher sentiment score.

Positives

• Net income attributable to InnovAge Holding Corp. significantly improved to $18.6 million for the six months ended December 31, 2025, compared to a net loss of $18.2 million in the prior year.
• Total revenues increased by 14.9% to $475.8 million, driven by strong capitation revenue growth of 15.0%.
• Adjusted EBITDA saw a substantial increase of 222.3% to $39.8 million, reflecting improved operating performance.
• The company's census grew, with member months increasing by 8.9% and total participants reaching approximately 8,010.
• Capitation rates increased by 5.6%, including an 8.0% rise in Medicaid rates and a 3.9% increase in Medicare rates.
• External provider costs per participant decreased by 5.7% for the six months ended December 31, 2025, primarily due to lower permanent nursing facility utilization and reduced pharmacy expense from the transition to in-house services.
• The company successfully refinanced its Term Loan Facility and extended the maturity date of both the Term Loan A Facility and the Revolving Credit Facility to August 8, 2028.
• A significant stockholder class action lawsuit was settled and closed, removing a material contingent liability.

Negatives

• Cost of care (excluding depreciation and amortization) increased by 18.3% to $150.8 million for the six months ended December 31, 2025, driven by higher wage rates, increased headcount, third-party fees for in-house pharmacy services, and fleet costs.
• Interest expense, net, increased by 77.4% to $2.5 million for the six months ended December 31, 2025, compared to $1.4 million in the prior year.
• The California Department of Health Care Services (DHCS) imposed a moratorium on PACE applications for all organizations, effective November 20, 2025, for a minimum of two years, impacting future de novo center expansion in the state.
• The company received a formal Corrective Action Plan (CAP) from DHCS for deficiencies identified in its San Bernardino center, with state attestations for planned California de novo centers contingent on successful remediation.
• Ongoing civil investigative demands from federal and state agencies (DOJ, Colorado Attorney General) related to Medicaid billing, patient services, and enrollment practices, with potential losses currently unestimable.
• Two separate legal proceedings with Grane Rx, a former pharmacy services vendor, are ongoing, including an arbitration and a lawsuit alleging breach of confidentiality and misappropriation of trade secrets, with potential losses unestimable.

Risks

• Increased cost of care from third-party service providers due to macroeconomic challenges, budget pressures from the One Big Beautiful Bill Act (OBBBA), and state Medicaid program budget cuts.
• Healthcare workforce shortages, particularly in geriatrics, primary care, and direct care roles, leading to labor competition, increased wage and benefit costs, and potential impacts on enrollment capacity and services.
• Uncertain access to supportive housing facilities for participants, as facilities may prioritize private payors or be unable to accept participants at pre-determined rates.
• Delays and increased gaps in eligibility for new enrollments and Medicaid redetermination applications due to processing delays and state-specific procedures, potentially exacerbated by the OBBBA.
• Mandated reductions in federal Medicaid spending, new work requirements, and cost-sharing measures under the OBBBA, which could lead to state budgetary pressures, reductions in optional Medicaid benefits, and downward pressure on capitated fee payments.
• Macroeconomic trends, including tariffs and trade disputes, potentially resulting in higher prices for medical and other supplies and supply chain disruptions.
• The California DHCS moratorium on PACE applications and the requirement to remediate deficiencies in existing centers could hinder the company's ability to expand via de novo centers in California.
• Ongoing legal proceedings, including civil investigative demands from federal and state agencies and disputes with a former vendor, could result in significant defense and settlement costs, diversion of management resources, and adverse impacts on operating results.
• The difficulty in predicting future operating results, which could cause results to fall below any guidance, targets, or goals provided.

Future Outlook

The company anticipates increased cost of care from third-party service providers in the second half of fiscal year 2026, but believes its clinical and operational value initiatives may help offset these increases. While processing delays for Medicaid enrollments and redeterminations have reduced, they could persist or worsen due to potential future impacts of the OBBBA. The company intends to retain substantially all available funds and future earnings to fund business development, growth, and debt repayment, and does not anticipate paying cash dividends in the foreseeable future. Future growth is expected to be supported by continued investment in centers, value-based care models, and sales and marketing, with an expectation of increased expenses in absolute dollars due to compliance and growth initiatives.

Management Comments

• "We believe that our clinical value initiatives and operational value initiatives, which continue to be developed, may assist us in offsetting the increased cost of care anticipated for the second half of fiscal year 2026."
• "To mitigate these challenges [labor market pressures], we implemented targeted compensation in line with the markets in which we operate and focused retention programs for critical roles, along with operational measures to help improve productivity and continue reducing reliance on agency staffing."
• "While processing delays generally reduced in measure during the first half of fiscal year 2026, it is possible that these delays could persist or be exacerbated due to potential future impacts of the OBBBA."
• "We plan to work closely with the State to fulfill the obligations of the CAP [for San Bernardino]."
• "While the planned California de novo centers are precluded from opening at this time, DHCS notified us that it would consider restoring the State Attestations upon our successful remediation of the deficiencies raised in our Sacramento center and its completion of the medical review, including the resultant remediation, in our San Bernardino center."
• "We currently intend to retain substantially all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and do not anticipate paying any cash dividends in the foreseeable future."

Industry Context

StockSavvy.ai notes that InnovAge operates within a healthcare sector experiencing significant workforce shortages, particularly in geriatrics and direct care roles, leading to increased competition and wage pressures. The company's PACE model, which serves frail, high-cost, dual-eligible seniors, positions it to receive larger risk-adjusted payments compared to standard Medicare Advantage programs. However, the industry is also facing federal and state efforts to reduce healthcare spending, such as the OBBBA, which could impact Medicaid funding and capitated rates. The challenges in accessing supportive housing facilities for an aging population further highlight systemic pressures on long-term care providers.

Comparison to Industry Standards

• InnovAge manages participants who are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (MA) programs, leading to larger capitated payments.
• The company reported an average risk adjustment factor (RAF) score of 2.50 as of December 31, 2025, indicating a higher acuity population compared to typical MA programs.
• Average participant tenure was 3.2 years as of December 31, 2025, among centers operated for at least five years, suggesting strong participant retention.
• Voluntary disenrollment rates averaged 7.0% annually over the last three fiscal years, indicating low participant churn relative to the comprehensive care model.

Legal Proceedings

• Ongoing civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act, requesting information on Medicaid billing, patient services, and referrals.
• Ongoing civil investigative demands from the Department of Justice (DOJ) under the Federal False Claims Act, requesting information on audits, billing, orders tracking, quality of patient services, and relationship with residential care facilities.
• Settlement of a stockholder class action complaint (Securities Action) for $27.0 million, with the company contributing $10.1 million after insurer adjustments; the case is now closed.
• Settlement in principle reached for a derivative lawsuit alleging breach of fiduciary duty against current and former officers and directors, expected to be fully funded by insurance proceeds.
• Ongoing arbitration with Grane Supply, Inc. d/b/a Grane Rx, the company's former pharmacy services vendor, for breach of contract, with a final merits hearing expected in March 2026.
• Separate lawsuit filed by Grane Rx in the Delaware Court of Chancery alleging breach of confidentiality obligations and misappropriation of trade secrets.

Related Party Transactions

• InnovAge entered into a joint venture agreement with Orlando Health (OHI) for InnovAge Florida PACE Orlando, with InnovAge contributing $26.1 million for a 90% interest and OHI contributing $2.9 million for a 10% interest.
• InnovAge entered into a joint venture agreement with Tampa General Hospital for InnovAge Florida PACE Tampa, with InnovAge contributing $28.8 million for a 90% interest and Tampa General Hospital contributing $3.2 million for a 10% interest.
• InnovAge Sacramento is a joint venture with Adventist Health System/West and Eskaton Properties, Incorporated, where InnovAge holds a 60% membership interest.

Stakeholder Impact

• Shareholders: Positive financial performance and resolution of a major lawsuit are beneficial, but ongoing regulatory challenges and legal proceedings, particularly the California moratorium, introduce uncertainty regarding future growth and could impact share price.
• Employees: Increased salaries, wages, and benefits, along with targeted compensation and retention programs, aim to address workforce shortages, but organizational restructure and executive severance indicate internal changes.
• Customers (PACE participants): The company's focus on improving quality of care and keeping participants in their homes is positive, but potential impacts from Medicaid spending cuts (OBBBA) and uncertain access to residential facilities could affect service delivery.
• Government Payors (Medicare/Medicaid): Continued reliance on capitated arrangements means the company is subject to government reviews, audits, and potential spending reductions, which could affect revenue streams.
• Suppliers: The transition to in-house pharmacy services and ongoing disputes with a former pharmacy vendor indicate shifts in supplier relationships and potential legal costs.

Next Steps

• Work closely with the California Department of Health Care Services (DHCS) to fulfill the obligations of the Corrective Action Plan (CAP) for the San Bernardino center.
• Successfully remediate deficiencies identified in the Sacramento center to potentially restore State Attestations for planned California de novo centers.
• Continue to develop and implement clinical and operational value initiatives to offset anticipated increases in the cost of care.
• Engage in the final merits hearing for the arbitration with Grane Rx, expected in March 2026.
• Adopt ASU 2023-09 in the company's annual consolidated financial statements for the year ending June 30, 2026.
• Evaluate the effects of ASU 2024-03 and ASU 2025-11 on consolidated financial statements and related disclosures.

Key Dates

Recommendation

The company has demonstrated a strong financial turnaround with significant revenue growth and a return to profitability, which are positive indicators. However, the ongoing regulatory challenges, particularly the California moratorium on new PACE applications and the need to remediate deficiencies, introduce substantial uncertainty regarding future expansion. Additionally, multiple ongoing legal proceedings, while some are settling, still pose potential financial and reputational risks. A seasoned investor would likely hold to observe the resolution of these regulatory and legal matters and assess the company's ability to navigate these headwinds and sustain its improved financial performance.

Keywords

PACE, Program of All-Inclusive Care for the Elderly, Healthcare, Managed Care, Capitation Revenue, Medicare, Medicaid, Elderly Care, Financial Results, SEC Filing, 10-Q, InnovAge, INNV, Risk Adjustment Factor, De Novo Centers, Regulatory Compliance, Workforce Shortages, Legal Proceedings